Novo Nordisk

<%= message.delivery.preHeader %>

Important Safety Information	\|	Prescribing Information	\|	Medication Guide

Alhemo^® is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A or B with or without factor VIII or IX inhibitors. It is not known if Alhemo^® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age.

WELCOME!

We’re so glad you’re here.

Thanks for signing up to learn more about Alhemo^®. When you’re ready to take the next step, our Novo Nordisk Rare Blood Community Liaisons (RBCLs) are available to support you. These are experts in the rare bleeding disorders community. Our RBCLs can provide you with resources and information about local events in your area, and are here to answer your questions about treatment options.

Here’s how an RBCL can help:

Demonstrate how the Alhemo^® pen works
Offer personalized product information
Talk one-on-one about what this treatment can offer

Want to connect with someone who can be there each step of the way?

Say hello to an RBCL

Important Safety Information for Alhemo^®

What is the most important information I should know about Alhemo^®?

	•	It is important to follow the daily dosing schedule of Alhemo^® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo^® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo^® without talking to your HCP. If you miss doses or stop using Alhemo^®, you may no longer be protected against bleeding
	•	Your HCP may prescribe factor VIII, factor IX, or bypassing agents during treatment with Alhemo^®. Carefully follow your HCP’s instructions regarding when to use on-demand factor VIII, factor IX, or bypassing agents and the recommended dose and schedule for breakthrough bleeds

Please click here or scroll below for additional Important Safety Information.

Keep scrolling to learn more about Alhemo^®

Powerful stories. Proven science.

Whether you’re curious about how Alhemo^® works or want to hear from someone who’s been where you are, we’ve got you covered. Explore empowering stories of people living with hemophilia—and get a closer look at the innovation behind Alhemo^®.

Discover Royal’s journey

Watch science in action

Royal lives with hemophilia B with inhibitors, uses Alhemo^®, and is an employee of Novo Nordisk.

What is Alhemo^®

Alhemo^® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A or B with or without factor VIII or IX inhibitors.

•

It is not known if Alhemo^® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age

Important Safety Information (cont’d)

Do not use Alhemo^® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo^®.

Before using Alhemo^®, tell your HCP about all of your medical conditions, including if you:

	•	Have a planned surgery. Talk to your HCP about when to stop using Alhemo^® and when to start it again if you have a planned surgery
	•	Are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if Alhemo^® may harm your unborn baby or if Alhemo^® passes into your breast milk

	◦	Your HCP may do a pregnancy test before you start treatment with Alhemo^®.
	◦	Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo^® and for 7 weeks after ending treatment

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements.

What are the possible side effects of Alhemo^®?

Alhemo^® may cause serious side effects, including:

	•	Blood clots (thromboembolic events). Alhemo^® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision
	•	Allergic reactions. Alhemo^® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo^® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat

The most common side effects of Alhemo^® include: bruising, redness, bleeding, itching, rash or lump at the injection site, headache, and hives. These are not all the possible side effects of Alhemo^®. Call your doctor for medical advice about side effects.

Please see Prescribing Information and Medication Guide for Alhemo^®.

Alhemo^® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please do not respond to this email. If you would like to contact us, please click here or call 1‑877‑744‑2579.

UNSUBSCRIBE NOTICE

If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement.

To ensure receipt of future emails, please add mail@communications.novonordiskmessage.com to your address book.